Our Investors
Backed by a premier group of life sciences investors committed to advancing potential new therapies for protein misfolding diseases.
Protego Bio is a clinical-stage biotechnology company developing first-in-class small molecule therapies for AL amyloidosis and other protein misfolding diseases. Our therapies are designed to address protein misfolding and toxicity, with the goal of preserving organ function and improving patients’ lives.
PROT-001 is an investigational oral small molecule designed to stabilize lambda light chains in AL amyloidosis. By targeting the light chain protein itself, PROT-001 is designed to complement plasma cell-directed therapies, which reduce light chain production.
PROT-001 is investigational. Its safety and efficacy in patients with AL amyloidosis have not been established.
Learn about PROT-001Developing pharmacological chaperones with the goal of improving the lives of patients with protein misfolding diseases.
Mission and values →Our integrated approach combines protein sciences, advanced computation, and medicinal chemistry.
Our strategy →Our lead clinical program focuses on AL amyloidosis, with broader research into other protein misfolding diseases.
Disease focus areas →Advancing multiple programs from target identification through clinical validation.
View the pipeline →The scientific origins of our approach to protein stabilization.
Scientific foundation →Decades of experience in drug discovery, clinical development, and biotechnology innovation.
Meet the Team →We're building a team of passionate scientists and professionals dedicated to bringing life-changing therapies to patients in need.
Backed by a premier group of life sciences investors committed to advancing potential new therapies for protein misfolding diseases.